The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TEM | +26.01% | N/A | N/A | +78% |
| S&P | +12.65% | +91.73% | +13.89% | +24% |
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful.
The company, which specializes in artificial intelligence (AI) functionalities to aid drug discovery, could be a powerhouse, according to one market professional.
A recent acquisition seems to be paying off already for the tech-forward healthcare data specialist.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $334.21M | 84.7% |
| Gross Profit | $205.91M | 100.3% |
| Gross Margin | 61.61% | 4.8% |
| Market Cap | $14.02B | 60.5% |
| Market Cap / Employee | $5.84M | 0.0% |
| Employees | 2.4K | 4.3% |
| Net Income | -$79.98M | -5.5% |
| EBITDA | -$32.91M | 25.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $655.92M | 69.0% |
| Accounts Receivable | $288.63M | 98.2% |
| Inventory | 55 | 52.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.32B | 184.2% |
| Short Term Debt | $12.42M | 110.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -12.53% | 0.0% |
| Return On Invested Capital | -88.81% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$126.55M | -360.3% |
| Operating Free Cash Flow | -$119.84M | -346.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 97.60 | 138.82 | 33.71 | 45.27 | -49.03% |
| Price to Sales | 7.89 | 10.24 | 11.57 | 12.78 | -12.72% |
| Price to Tangible Book Value | -154.56 | -272.31 | -27.55 | -34.70 | -103.44% |
| Enterprise Value to EBITDA | -142.52 | -197.83 | -364.68 | -446.51 | 110.31% |
| Return on Equity | -98.0% | -72.6% | - | ||
| Total Debt | $468.09M | $857.75M | $853.25M | $1.34B | 183.29% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
